October 19th 2020
By Tony Hagen
An Avalere analysis suggests costs are more moderate and lower under a no–step therapy scenario for patients with Crohn disease.
October 14th 2020
Amgen's 2020 biosimilar report goes into detail on market share and costs for biosimilars across the therapeutic spectrum in the United States.
Alexion and Celltrion separately announce advances in their drug development and marketing efforts.
October 13th 2020
Years ahead of patent expirations for programmed death-1 (PD-1) inhibitors, biosimilar companies have begun focusing on these targeted drugs.
October 10th 2020
By Skylar Jeremias
Average clinical efficacy testing cost millions of dollars more for phase 3 biosimilar studies than for pivotal studies of originator products, authors report.
October 9th 2020
As the United States continues to struggle to increase biosimilar uptake, presenters at the DIA 2020 Biosimilars Conference offered insight into what other countries have done to encourage biosimilar use.
October 8th 2020
Simplified standards for biosimilar approvals in the United Kingdom may open the door to broader changes.
October 7th 2020
The FDA has had to rely on triaging to address its most critical priorities during the unfolding coronavirus disease 2019 (COVID-19) pandemic, according to Peter P. Stein, MD.
October 6th 2020
A report from the IQVIA Institute for Human Data Science states that assessments of the health of the US biosimilar market are too conservative.
The European Medicines Agency (EMA) regulatory review advances a pact between Samsung Bioepis and Biogen announced last year.
